Skip to main content
. 2016 Feb;54(2):241–249. doi: 10.1165/rcmb.2015-0079OC

Figure 3.

Figure 3.

Methylated PDE4D inhibited cell proliferation and migration of asthmatic ASMCs. (A) Cell viability assayed by alamarBlue and (B) cell migration examined by chemotaxis assay in nonasthmatic (three donors) and asthmatic (three donors) ASMCs treated with LF with or without PDE4D-targeting (M-PDE4D) or nontargeting methylated oligonucleotide control (M-CTL). *P < 0.05 in comparison to LF control of nonasthmatic ASMCs; #P < 0.05 in comparison to M-CTL of asthmatic ASMCs.